In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Concert partners deuterium-modified drug candidates with GSK

Executive Summary

In its first drug development collaboration ever, Concert Pharmaceuticals (deuterium chemistry platform that modifies existing small molecules) has granted GlaxoSmithKline options to exclusively license global rights to three of its deuterium-containing drug candidates.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register